Copyright
©The Author(s) 2016.
World J Gastroenterol. Oct 28, 2016; 22(40): 8967-8977
Published online Oct 28, 2016. doi: 10.3748/wjg.v22.i40.8967
Published online Oct 28, 2016. doi: 10.3748/wjg.v22.i40.8967
Figure 5 Cumulative survival rates of control and deferasirox-treated mice in a murine hepatocellular carcinoma model.
Deferasirox (DFX)-treated mice showed significantly higher survival rate than control mice (P < 0.01).
- Citation: Saeki I, Yamamoto N, Yamasaki T, Takami T, Maeda M, Fujisawa K, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Uchida K, Tani K, Sakaida I. Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(40): 8967-8977
- URL: https://www.wjgnet.com/1007-9327/full/v22/i40/8967.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i40.8967